SHP Activators

The chemical class of NR0B2 gene product activators, commonly known as Short Heterodimer Partner (SHP), encompasses a diverse array of compounds that modulate the regulatory functions of this nuclear receptor. SHP, encoded by the NR0B2 gene, plays a pivotal role in metabolic homeostasis, acting as a transcriptional corepressor and regulator of various signaling pathways. The activation of SHP is intricately linked to the modulation of its interacting partners, particularly the Farnesoid X Receptor (FXR), a nuclear receptor involved in bile acid and lipid metabolism. One notable activator, cholic acid, a primary bile acid, initiates the activation of SHP through its interaction with FXR. This interaction forms a complex that suppresses the transcription of key genes involved in bile acid synthesis, contributing to the maintenance of cholesterol homeostasis. Another synthetic FXR agonist, GW4064, serves as a potent activator of SHP. By binding to FXR, GW4064 elicits downstream effects that repress hepatic gluconeogenesis and downregulate genes associated with bile acid synthesis.

Rifampicin, a well-known antibiotic, induces SHP expression by activating the pregnane X receptor (PXR). This activation, in turn, leads to the suppression of CYP7A1 and other target genes involved in bile acid synthesis. Deoxycholic acid, a secondary bile acid, activates SHP through FXR, contributing to the regulation of lipid metabolismTauroursodeoxycholic Acid (TUDCA) activates SHP through FXR, leading to the suppression of bile acid synthesis and protection against endoplasmic reticulum stress-induced apoptosis. Guggulsterone activates SHP through FXR, contributing to the regulation of cholesterol and lipid metabolism. Fexaramine, a selective FXR agonist, activates SHP, leading to the repression of bile acid synthesis and modulation of metabolic processes. Lithocholic acid activates SHP through FXR, inhibiting bile acid synthesis and maintaining cholesterol homeostasis. LXR-623, a liver X receptor (LXR) agonist, indirectly activates SHP, contributing to the inhibition of cholesterol synthesis and the maintenance of lipid homeostasis. Lastly, oleanolic acid activates SHP through FXR, leading to the repression of bile acid synthesis and regulation of lipid metabolism.